As more and more litigation emerges over an off-patent drug with a purported ability to treat COVID-19, judges are increasingly finding themselves in a bind: forced to ponder the merits of unapproved treatment and essentially second-guessing physicians whose patients don’t get what they want.

That’s generated concern among health-care lawyers, some of whom see growing requests for the anti-parasite drug Ivermectin as a Hail Mary attempt to keep loved ones alive.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]